整合素相关蛋白CD47在乳腺癌中表达临床意义

Expression of CD47 is the Clinic Significance of in Breast Cancer

目的:探讨整合素相关蛋白CD47在乳腺癌中表达的临床意义。方法:应用MaxVinsion免疫组织化学技术对浸润性导管癌患者63例进行CD47表达标记。结果:63例浸润性导管癌患者阳性表达率为80.9%,CD47阳性表达率与患者年龄、肿瘤大小及TNM分期比较,结果有非常显著性差异,CD47阳性表达率与乳腺癌组织学分级和腋窝淋巴结转移情况结果比较,无显著性差异,并且CD47阳性表达率与肿瘤分子表型的雌激素(Estrogen receptor,ER)、孕激素(Progestcrone receptor,PR)、细胞表皮生长因子2(Cell epidermal growth factor,CerBb-2)的阳性结果比较,结果比较有显著性差异,CDK2阳性表达与肿瘤分子分型增殖指数ki67结果比较无显著性差异。结论:CD47是浸润性导管癌乳腺患者有效的预后因子。

Objective： To Explore the clinic significance of the positive expression of CD47 in the treatment of breast cancer. Method： Expression of CD47 markers in 63 patients with infiltrating ductal carcinoma were detected Using MaxVinsion immune-histochemical techniques. Results： The expression of CD47 was positive in 51 cases of 63 patients with infiltrating ductal carcinoma, and the positive rate was 80.9%. There was significant difference between the positive of CD47 expression and its clinical pathological features （age, tumor size and TNM stage）. There was the significant difference between the positive of CD47 expression and the expression of ER, PR, and CerBb-2 positive expression. There was no significant difference between the positive of CD47 expression and the expression of ki67 positive expression, the tumor grade and lymph matestasis. Conclusion： CD47 can be used as the prognostic factor ofinvasive ductal breast cancer.